Physician profile
Eric C Bekemeier
NPI 1053518274
$3,380.03
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $134 · 2021: $839 · 2022: $1,051 · 2023: $758 · 2024: $29.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $492.90 | 2021-2023 | |
| Abbvie INC. | $478.01 | 2019-2024 | Qulipta |
| Pfizer INC. | $350.09 | 2019-2023 | |
| Abbott Laboratories | $314.95 | 2019-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $259.47 | 2019-2023 | Shingrix, Bexsero |
| Lilly USA, LLC | $179.17 | 2021-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $150.46 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $128.94 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.13 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $94.84 | 2021 | |
| Merck Sharp & Dohme LLC | $86.00 | 2019-2021 | |
| Astellas Pharma US INC | $77.78 | 2019-2021 | |
| Sanofi Pasteur INC. | $70.18 | 2019-2023 | |
| Novo Nordisk INC | $66.96 | 2020-2023 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $43.59 | 2022-2023 | Wavewriter Alpha Prime 16 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $39.10 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.69 | 2021-2022 | |
| Esperion Therapeutics, INC. | $38.43 | 2021-2023 | Nexletol |
| Exact Sciences Corporation | $35.76 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $28.31 | 2019 | |
| Amgen INC. | $27.94 | 2022 | |
| Horizon Therapeutics Plc | $26.06 | 2022 | |
| Alfasigma USA, INC. | $25.61 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.88 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.95 | 2022 | |
| Phadia US INC. | $18.41 | 2023 | Immunocap |
| Hologic Sales and Service, LLC | $17.85 | 2023 | Thinprep 2000 Processor, Aptima |
| Arbor Pharmaceuticals, INC. | $17.26 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.24 | 2021 | |
| Seqirus USA INC | $15.77 | 2022 | |
| Qiagen, LLC | $15.63 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.12 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.09 | 2022 | |
| Dexcom, INC. | $14.66 | 2022 | |
| Philips North America LLC | $13.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bekemeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.